Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC

  • Federica Brugnoli1,
  • Silvia Grassilli1,
  • Paola Lanuti2, 3,
  • Marco Marchisio2, 3,
  • Yasamin Al-Qassab1, 4,
  • Federica Vezzali1,
  • Silvano Capitani1, 5 and
  • Valeria Bertagnolo1Email author
BMC Cancer201717:617

https://doi.org/10.1186/s12885-017-3592-y

Received: 17 November 2016

Accepted: 22 August 2017

Published: 4 September 2017

Abstract

Background

The malignant potential of triple negative breast cancer (TNBC) is also dependent on a sub-population of cells with a stem-like phenotype. Among the cancer stem cell markers, CD133 and EpCAM strongly correlate with breast tumor aggressiveness, suggesting that simultaneous targeting of the two surface antigens may be beneficial in treatment of TNBC. Since in TNBC-derived cells we demonstrated that PLC-β2 induces the conversion of CD133high to CD133low cells, here we explored its possible role in down-modulating the expression of both CD133 and EpCAM and, ultimately, in reducing the number of TNBC cells with a stem-like phenotype.

Methods

A magnetic step-by-step cell isolation with antibodies directed against CD133 and/or EpCAM was performed on the TNBC-derived MDA-MB-231 cell line. In the same cell model, PLC-β2 was over-expressed or down-modulated and cell proliferation and invasion capability were evaluated by Real-time cell assays. The surface expression of CD133, EpCAM and CD44 in the different experimental conditions were measured by multi-color flow cytometry immunophenotyping.

Results

A CD133+/EpCAM+ sub-population with high proliferation rate and invasion capability is present in the MDA-MB-231 cell line. Over-expression of PLC-β2 in CD133+/EpCAM+ cells reduced the surface expression of both CD133 and EpCAM, as well as proliferation and invasion capability of this cellular subset. On the other hand, the up-modulation of PLC-β2 in the whole MDA-MB-231 cell population reduced the number of cells with a CD44+/CD133+/EpCAM+ stem-like phenotype.

Conclusions

Since selective targeting of the cells with the highest aggressive potential may have a great clinical importance for TNBC, the up-modulation of PLC-β2, reducing the number of cells with a stem-like phenotype, may be a promising goal for novel therapies aimed to prevent the progression of aggressive breast tumors.

Keywords

Triple-negative breast cancer (TNBC)CD133EpCAMPLC-β2Breast cancer stem cell (BCSC)ProliferationInvasiveness

Background

Triple-negative breast cancer (TNBC), which accounts for 10% to 24% of invasive breast cancers, is typically a high-grade tumor with a great propensity to metastasize [1]. Different studies grouped TNBC on the basis of immunophenotype and of RNA and DNA genomic profiles, identifying subtypes with variable potentiality of aggressiveness. In all studies, the more aggressive subtypes were those associated with the expression of immunomodulatory and stem-like molecules [2, 3]. In particular, the ability of TNBC cells to proliferate, progress, and spread is also based on a limited sub-population of cells with properties similar to stem cells, defined as “breast cancer stem cells” (BCSCs) [4]. Several stemness markers have been described to identify BCSCs, such as CD44, CD24, CD133, EpCAM, CD166, Lgr5, CD47, ALDH1, and ABCG2 [5, 6]. Since their expression profiles showed a large variability within breast cancer subtypes, especially for TNBCs, none of them may be singly correlated with prognosis or with specific therapies of TNBC patients [3, 5]. It is then undoubted that the simultaneous targeting of various markers expressed on BCSCs may have advantage in the treatment of highly aggressive breast tumors. In this context, CD133 and EpCAM are highly promising target antigens since, beyond to be markers of BCSCs, they have a direct relationship with malignancy of breast tumors. In particular, CD133 expression in breast cancer significantly correlates with tumor stage, tumor size, occurrence of lymph node metastases and sensitivity to neoadjuvant chemotherapy [7, 8]. In TNBC, CD133+ cells with cancer stem cell characteristics associate with vasculogenic mimicry [9]. The recent use of CD133 to detect circulating tumor cells in TNBC patients [10] has increased attention to this marker highlighting its role in establishing prognostic and predictive value in TNBCs. Concerning EpCAM, its over-expression was observed in up to 70% of breast tumors in which it strongly correlates with a higher risk of recurrence [11]. The use of EpCAM as a marker for detecting disseminated breast cancer cells in bone marrow strongly suggests that EpCAM+ breast cancer cells possess an enhanced ability to metastasize [12]. Nevertheless, the sole over-expression of CD133 or EpCAM in TNBC was correlated with poorer prognosis in about 60% of tumors [13, 14]. This evidence, on one hand, indicates that the selective removal of CD133+ or EpCAM+ cells may not be sufficient to eradicate cells with the most aggressive phenotype, like cancer stem cells, and on the other hand that the simultaneous targeting of the two surface antigens may be of clinical relevance in treatment of TNBC patients. In recent years, a toxin-based system to simultaneously target CD133 and EpCAM in the same cell was developed in different carcinoma models, including inflammatory breast carcinoma, showing a potent inhibition of proliferation in vitro and the regression of HNSCC (Head and neck squamous cell carcinoma) in vivo [15]. Despite these encouraging results, the use on human tumors is far for being advantageous, due to the high costs of toxin generation and, more importantly, to the off-target effects or to the generation of anti-toxin antibodies having adverse effects against extended treatments [16].

In breast tumor-derived cells with different phenotypes, we demonstrated that the expression of CD133 is strongly correlated to the levels of the beta2 isoform of the phosphoinositide-dependent phospholipase C (PLC-β2) [17, 18], ectopically expressed in the large majority of primary invasive mammary tumors of all histological subtypes [19]. Consistently, we also found that in both MDA-MB-231 and MDA-MB-468 cells, showing a TNBC basal-B and a basal-A phenotype, respectively [20], the over-expression of PLC-β2 induced the conversion of CD133high to CD133low cells [17].

Here we explored the possible role of PLC-β2 in modulating the expression of both CD133 and EpCAM in triple-negative breast tumor cells, in order to assess if strategies aimed to up-modulate this PLC isozyme may be useful in reducing the expression of these BCSCs markers and, eventually, in reducing the number of cells with a stem-like phenotype.

Methods

All reagents were from Sigma (St Louis, MO) unless otherwise indicated.

Cell culture

The breast cancer-derived cell lines MDA-MB-231 (HTB-26), MDA-MB-468 (HTB-132) and MCF7 (HTB-22) were purchased from the American Type Culture Collection (Rockville, MD) and grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco Laboratories), at 37 °C in a humidified atmosphere of 5% CO2 in air. Cells were monthly tested for mycoplasm and other contaminations and quarterly subjected to cell identification by single-nucleotide polymorphism. Cell viability was determined with a hemocytometer-based Trypan blue dye exclusion cell quantification.

Immunophenotyping

The expression of CD133, EpCAM and CD44 surface antigens were evaluated by flow cytometry following a previously described procedure [21]. In a one-tube assay, cells were stained with phycoerythrin (PE)-conjugated anti-CD133/2 (293C3) and fluorescein isothiocyanate (FITC)-conjugated anti-CD326 (EpCAM) (Miltenyi Biotec, Bologna, I) or with PE-conjugated anti-CD133, FITC-conjugated anti-EpCAM and allophycocyanin (APC)-conjugated anti-CD44 (Becton Dickinson, San José, CA) monoclonal antibodies. All samples were analyzed by a FACSCalibur flow cytometer (Becton Dickinson) with the CellQuest Pro 6.0 software (Becton Dickinson). 20,000 non-debris events in the morphological gate were recorded for each sample. All antibodies were titrated under assay conditions and optimal photomultiplier (PMT) gains were established for each channel, as previously reported [22].

Data were analysed using FlowJo™ software (TreeStar, Ashland, OR) and reported as percentage of positive cells or as mean fluorescence intensity (MFI) values.

Magnetic step-by-step cell isolation

MDA-MB-231 sub-populations enriched in CD133+ and/or EpCAM+ cells were obtained by means of the MACS immunomagnetic separation system, essentially as described by Pierzchalski et al. [23]. In particular, cells were firstly labeled with CD133/1 MicroBeads (Miltenyi Biotech) and subjected to positive magnetic cell separation through MACS SD columns in the field of the MACS magnet (Miltenyi Biotech), according to manufacturer’s instructions. Both CD133 and CD133+ cells were then subjected to a second positive selection after magnetic labelling with CD326 MicroBeads (Miltenyi Biotech). The obtained CD133/EpCAM, CD133/EpCAM+, CD133+/EpCAM and CD133+/EpCAM+ enriched sub-populations were cultured in the above reported medium and subjected to cytofluorimetrical analysis, to invasion assays and to modulation of PLC-β2 expression.

Cell proliferation and invasion assays

Proliferation and invasiveness of cellular subsets derived from magnetic separation were determined by means of the xCELLigence Real-Time Cell Analyzer System (RTCA, Acea Bioscences Inc., San Diego, CA), developed to monitor cell events in real time by measuring the electrical impedance produced by cells, as previously reported [17]. In particular, to measure cell proliferation, 5000 cells/well were plated and signal detection was enabled every 15 min up to 96 h. For the invasion assay, 40,000 cells/well were seeded onto the top chambers covered with a layer of Matrigel (Becton Dickinson) diluted 1:20. The bottom chambers were filled with medium containing 10% serum and the signal was detected every 15 min for a total of 24 h.

Cell invasion was also evaluated by means of Boyden Chamber assays according to the protocol recommended from Chemicon (Tamecula, CA). The Cell Invasion Assay Kit (ECM550) is made up of invasion chambers containing inserts with an 8 μm pore size polycarbonate membrane over which a thin layer of ECMatrix™ solution was applied, following a procedure previously reported [24].

Immunofluorescence analysis

Cellular populations derived from magnetic separation were grown onto glass slides, fixed with freshly prepared 4% paraformaldehyde, washed in PBS and reacted with the anti-PLC-β2 (#SC-206, Santa Cruz Biotechnology, Santa Cruz, CA) antibody in a Net Gel solution, alone or in combination with the anti-CD133 (W6B3C1, Miltenyi Biotech) or with the anti-EpCAM (NCL-ESA, Leica Biosystems, Buccinasco, I) antibodies, respectively, following a previously reported procedure [18]. Samples were then incubated with a FITC and/or TRITC conjugated secondary antibody and, after washes, with 0.5 mg/ml 4',6-diamidino-2-phenylindole (DAPI), dried with ethanol and mounted in glycerol containing 1,4-diazabicyclo [2.2.2] octane (DABCO) to retard fading. Fluorescent samples were observed with a Nikon Eclipse TE2000-E microscope (Nikon), acquiring cell images by the ACT-1 software for a DXM1200F digital camera (Nikon S.p.a., Florence, I). To measure PLC-β2 staining, digitized images were analyzed with the ImageJ software, following the manufacturer’s instructions (http://rsb.info.nih.gov/ij/).

Modulation of PLC-β2 expression

PLC-β2 over-expression was performed by transient transfection with a plasmid expressing a full-length human PLC-β2 and the specific down-modulation of the PLC was achieved by using specific siRNAs (Santa Cruz Biotechnology), following previously described procedures [18]. An empty vector and a non-silencing scramble siRNAs, respectively, were used as negative controls. The transfected cells were incubated at 37 °C in a 5% CO2 atmosphere for 48 h then subjected to RTCA and to cytofluorimetrical analysis.

Statistical analysis

Statistical analysis was performed by using the two-tailed Student’s t-test for unpaired data. P values <0.05 were considered statistically significant.

Results

A MDA-MB-231 sub-population expressing high surface levels of CD133 and EpCAM shows elevated proliferation and invasion capability

By means of a cytofluorimetrical approach, we confirmed the existence of cells expressing CD133 at surface level in the highly tumorigenic TNBC derived MDA-MB-231 cell line and we revealed that almost 90% of cells result EpCAM+ (Fig. 1a). As expected [14, 25], the mean expression level of EpCAM in MDA-MB-231 cell, showing a mesenchymal-like phenotype (basal-B TNBC), is definitely lower than that of MCF7 cells, sharing a luminal B phenotype and low invasive potential, and of MDA-MB-468, a TNBC derived cell line with an epithelial-like phenotype (basal-A TNBC) and moderately invasive, 100% expressing high levels of CD133 (Additional file 1: Fig. S1A, B).
Fig. 1

Expression of CD133 and EpCAM in MDA-MB-231 cells. In a representative cytofluorimetrical evaluation of CD133 and EpCAM surface levels in MDA-MB-231 cells after labelling with a PE-conjugated anti-CD133 antibody or with a FITC-conjugated anti-EpCAM antibody. The expression of each antigen is shown, on the left, on a frequency distribution histogram (count vs. PE or FITC signal) in which the mean fluorescence intensity (MFI) of the entire population is reported. The red filled histograms represent positive staining for CD133 or EpCAM and the open histograms, outlined by gray lines, show staining with isotype matched antibodies. On the right, surface expression of each antigen is shown on a biparametric dot plot and the percentage and MFI of positive cells are indicated. In b representative surface expression of both CD133 and EpCAM in MDA-MB-231 cells after double labelling with a PE-conjugated anti-CD133 and with a FITC-conjugated anti-EpCAM antibodies is shown on a biparametric dot plot and the percentage of cells in all the derived quadrants is indicated

The contemporary use of the anti-CD133 and anti-EpCAM antibodies showed the presence of MDA-MB-231 cells expressing different levels of the two antigens at surface levels and allowed to identify a CD133+/EpCAM+ sub-population, accounting for about 3% of cells (Fig. 1b).

At variance with hepatocellular carcinoma (HCC), in which the features of cells with different CD133/EpCAM phenotypes were subjected to both in vitro and in vivo characterization [26], no information is available on TNBC derived cells showing variable surface levels of the two antigens. In order to study the correlation of CD133 and/or EpCAM with malignant features of MDA-MB-231, a magnetic step-by-step cell isolation with antibodies directed against the two surface antigens was performed. Since CD133+ cells are rare elements in the MDA-MB-231 cell population, we applied the MACS technique instead of the currently used Fluorescence-Activated Cell Sorting, thus ensuring the achievement of a relatively high number of cells in a short time [17, 23]. We obtained populations enriched in CD133/EpCAM, CD133/EpCAM+, CD133+/EpCAM or CD133+/EpCAM+ cells (Fig. 2). In particular, both CD133/EpCAM+ and CD133+/EpCAM+ sub-populations showed a relatively high mean expression level of EpCAM, indicating that the applied isolation procedure selected the cells with the higher surface levels of this adhesion molecule (Fig. 2).
Fig. 2

CD133 and EpCAM surface levels in MDA-MB-231 sub-populations. MDA-MB-231 cells were subjected to positive immunomagnetic separation after labeling with MicroBeads-conjugated anti-CD133 antibody followed by the positive selection through column of cells labeled with MicroBeads-conjugated anti-EpCAM antibody. Surface levels of CD133 and EpCAM were evaluated in all sub-populations after double labelling with a PE-conjugated anti-CD133 and with a FITC-conjugated anti-EpCAM antibody. The expression of each antigen is shown on a frequency distribution histogram (count vs. PE or FITC signal) in which the MFI of the entire population is reported. The red filled histograms represent positive staining for CD133 or EpCAM and the open histograms, outlined by gray lines, show staining with matched isotype antibodies. The dot plot analysis was used to assess the enrichment in CD133/EpCAM, CD133/EpCAM+, CD133+/EpCAM and CD133+/EpCAM+ cells in all subsets and the percentage of the main cell phenotype in each enriched sub-population is indicated. The data are indicative of three separate experiments

All sub-populations, grown in the same standard conditions, showed viability comparable to control cells and stable CD133 and EpCAM expression levels up to at least 3 passages in monolayer culture (data not shown).

Since we previously demonstrated that CD133high TNBC derived cells exhibit low proliferation rate but high invasion capability through Matrigel [17] and owing to the evidence that specific down-modulation of EpCAM decreases proliferation in the MDA-MB-231 cell line [25, 27] all sub-populations were subjected to analysis of proliferation and invasiveness. As shown in Fig. 3, the CD133+/EpCAM+ enriched cell population revealed the highest proliferation rate, measured in cells directly derived from magnetic separation (Fig. 3a) as well as in cells that, after 24 h from separation, were subjected to the xCELLigence assay (Fig. 3b, c).
Fig. 3

CD133 and EpCAM related proliferation and invasion capability of MDA-MB-231 sub-populations. Cells derived from immunomagnetic separations were immediately grown in culture medium for 96 h and daily counted by hemocytometer after Trypan Blue staining (a). After 24 h from separation, the cellular subsets were subjected to dynamic monitoring of proliferation (b) and invasion through Matrigel (d) using the xCELLigence RTCA system. Cell Index (CI) is reported and error bars indicate ±SD. The correspondent Slope analysis, that describes the steepness, incline, gradient, and changing rate of the CI curves over time, is shown in c and e respectively. In f a representative image of ECM invading cells in a Boyden Chamber assay, whose number is reported in g. The data are the mean of three separate experiments ± SD. The asterisks indicate statistically significant differences (P < 0.05)

Concerning invasion aptitude, both the xCELLigence strategy (Fig. 3d, e) and the classical ECM invasion assay (Fig. 3f, g) revealed for the two CD133+ enriched sub-populations a significantly higher capability to pass through Matrigel, consistent with our previous results obtained in the same cell line [17]. At variance, no difference in invasion capability were correlated with the expression levels of EpCAM in the different sub-populations (Fig. 3d-g).

PLC-β2 down-modulates the expression of both CD133 and EpCAM in the CD133+/EpCAM+ MDA-MB-231 sub-population.

In breast tumor derived cell lines with different phenotypes, including MDA-MB-231, we previously found that the level of CD133 inversely correlates with that of PLC-β2 [17]. By means of immunocytochemical analysis, here we confirmed that the two purified CD133 cellular subsets contain a PLC-β2 amount significantly higher than the CD133+ enriched sub-populations (Fig. 4a, b). While the PLC-β2 level in CD133 cells appeared unrelated to EpCAM expression, cells expressing high levels of the two antigens at surface level showed the lowest PLC-β2 (Fig. 4a, b). A double staining of PLC-β2 and EpCAM or CD133 was performed on the CD133/EpCAM and CD133+/EpCAM+ subsets and the immunofluorescence analysis showed that populations are homogeneous in terms of PLC-β2 expression and in terms of its relationship with the surface antigens (Fig. 4c).
Fig. 4

PLC-β2-related features in sub-populations enriched in CD133+ and/or EpCAM+ cells. In a representative fluorescence microscopy images of MDA-MB-231 sub-populations enriched in CD133/EpCAM, CD133/EpCAM+, CD133+/EpCAM and CD133+/EpCAM+ cells subjected to immunocytochemical analysis with the anti-PLC-β2 antibody. The fluorescence intensity of PLC-β2 staining was calculated in digitized images by the ImageJ software and reported in b as arbitrary units. In c immunocytochemical analysis of the indicated sub-populations after simultaneous staining with the anti-PLC-β2 antibody (green fluorescence) and with the anti-CD133 or anti- EpCAM antibody (red fluorescence). In d the enriched CD133+/EpCAM+ sub-population was transfected with siRNAs specific for PLC-β2 (PLC-β2 siRNAs) or with a construct expressing the human PLC-β2 (Over PLC-β2) and subjected to simultaneous flow cytometry analysis of CD133 and EpCAM surface expression. Non-silencing scramble siRNAs or an empty vector were used as controls (Ctrl). In each experimental condition, fold change is compared with Ctrl, taken as 1. Proliferation and invasiveness of cells in the same experimental conditions were measured by the xCELLigence system (e). All the data are the mean of three separate experiments performed in triplicate ± SD. *P < 0.05. Bar = 20 μm

As in both MDA-MB-231 and MDA-MB-468 we previously found that the over-expression of PLC-β2 induced the CD133high to CD133low conversion [17], the role of the PLC isozyme in modifying CD133 and/or EpCAM was investigated. PLC-β2 was then over-expressed in the CD133+/EpCAM+ enriched sub-population, which shows the lowest level of the protein, demonstrating a significant decrease of the surface expression of both antigens (Fig. 4d), in parallel with reduced proliferation and invasion aptitude (Fig. 4e).

PLC-β2 down-modulates MDA-MB-231 sub-populations with a stem-like phenotype

Once established that PLC-β2 may affect the levels of both CD133 and EpCAM in TNBC derived cellular subsets, we investigated its possible role in affecting, in the entire population, the number of cells expressing the two surface antigens. A cytofluorimetrical analysis was then performed on MDA-MB-231 cells in which PLC-β2 was forcedly up-modulated, demonstrating a substantial decrease of the CD133+/EpCAM+ sub-population and the concomitant increase of CD133/EpCAM and CD133+/EpCAM cells (Fig. 5a, b). Accordingly, an opposite effect was obtained by silencing PLC-β2 (Fig. 5a, b).
Fig. 5

Relationship between PLC-β2 and MDA-MB-231 sub-populations with a stem-like phenotype. In a MDA-MB-231 cells transfected with siRNAs specific for PLC-β2 (PLC-β2 siRNAs) or with a construct expressing human PLC-β2 (Over PLC-β2) were subjected to a bi-parametric flow cytometry by direct staining with the anti-CD133 and anti-EpCAM fluorescent antibodies to evaluate the number of CD133/EpCAM, CD133/EpCAM+, CD133+/EpCAM and CD133+/EpCAM+ cells. Non-silencing scramble siRNAs or an empty vector were used as control (Ctrl). The data, representative of three separate experiments, are presented on pie charts and the percentage of each cellular subset is reported. In b MDA-MB-231 cells in which PLC-β2 was forcedly silenced (PLC-β2 siRNAs) or over-expressed (Over PLC-β2) were simultaneously stained with APC-conjugated anti-CD44, FITC-conjugated anti-EpCAM and PE-conjugated anti-CD133 and subjected to flow cytometry evaluation of CD44, EpCAM and CD133 surface levels. Data are the mean of three separate experiments performed in triplicate ± SD. *P < 0.05

To better investigate the role of PLC-β2 in modulating the phenotype of TNBC cells, a cytofluorimetrical analysis after the contemporary staining with the anti-CD44, anti-CD133 and anti-EpCAM antibodies was performed in MDA-MB-231 cells in which the protein was forcedly modulated. As shown in Fig. 5b, no CD44 cells were detected in the wild-type population and in cells in which the PLC was silenced. On the other hand, the over-expression of PLC-β2 reduced the number of cells with a CD44+/CD133+/EpCAM+ phenotype (Fig. 5b) and induced the appearance of a small population of CD44−/CD133−/EpCAM+ cells (Fig. 5b).

Discussion

Unlike other subtypes of breast carcinomas, TNBC lacks a specific targeted therapy and its tumor heterogeneity requires subclass-dependent treatments, often not sufficient to avoid worse prognosis [1, 2]. BCSCs have been suggested to contribute to the increased aggressiveness and poor prognosis of TNBC. However, the high intratumor stemness heterogeneity reduces the prognostic and therapeutic value of the presence of tumor-initiating cells in this breast tumor subtype [28]. Among the stemness markers in TNBC, CD133 and EpCAM may be of interest since they have a direct relationship with malignancy of breast tumors. In particular, TNBC derived cells expressing high levels of CD133 show larger adhesion area and lower proliferation rate, indicative of a less undifferentiated phenotype, but higher invasive capability and increased expression of proteins involved in metastasis and drug-resistance of breast tumors [17]. Epigenetic changes (DNA methylation, acetylation, chromatin modification, microRNA, etc.) have also been correlated with CD133 in TNBC breast cancer stem cells, possibly related to the nuclear localization of this glycoprotein [29]. On the other hand, the adhesion molecule EpCAM is generally expressed by TNBC at levels reflecting the different subtypes, being over-expressed in basal-A and very low or absent in basal-B subtypes [14]. In TNBC derived cells, EpCAM can significantly promote the proliferation [30] but its role in invasiveness seems to be strikingly correlated with the specific subtypes [31].

In lung cancer, cells over-expressing both CD133 and EpCAM are more abundant than in normal tissues [32] and, in HCC derived cells, the CD133+/EpCAM+ sub-population shows increased colony-formation ability, drug-resistance, more spheroid formation by cultured cells and stronger tumorigenicity in NOD/SCID mice [26]. Here we correlated the simultaneous expression of CD133 and EpCAM with malignancy of breast tumor cells revealing the unprecedented evidence that a CD133+/EpCAM+ sub-population with more aggressive potential is present in the MDA-MB-231 cell line, showing a basal-B TNBC phenotype [25]. In particular, we found that the CD133+/EpCAM+ enriched cell population showed high proliferation rate, confirming the role described for the adhesion molecule in regulating growth of TNBC derived cells [14] but also suggesting that the contemporary surface localization of CD133 and EpCAM identifies a subset of cells with enhanced in vitro growth rate. Concerning invasion capability, the CD133+ enriched sub-populations showed a significantly higher capability to pass through Matrigel, consistent with our previous results obtained in the same cell line [17]. We failed to correlate invasion capability with the different expression levels of EpCAM, according with the results obtained by over-expressing the adhesion molecule in this cell line [27]. Our in vitro results indicate that a CD133+/EpCAM+ population with high proliferation rate and invasive potential may have a role in progression of TNBC, as already hypothesized for HCC and lung cancer [26, 32].

In breast tumor derived cell lines with different phenotypes we previously found that the level of CD133 inversely correlates with PLC-β2 and that over-expression of this PLC isozyme in MDA-MB-231 cells down-modulates CD133 at both membrane and intracellular levels [17]. Here we confirmed that the CD133 cellular subsets contain a PLC-β2 amount significantly higher than the CD133+ enriched sub-populations and we demonstrated that the concomitant presence of CD133 and EpCAM at surface level characterizes the MDA-MB-231 cells with the lowest PLC-β2 level. In addition, we found that the forced expression of PLC-β2 in the CD133+/EpCAM+ subset significantly reduced the surface expression of both antigens. A concomitant reduction of both proliferation and invasion was observed, confirming our previous results indicating that up-regulation of PLC-β2 in triple negative cells expressing high levels of CD133 reduces their invasion capability [17] but also suggesting that PLC-β2, down-modulating EpCAM, negatively affects proliferation of TNBC derived cells.

When PLC-β2 was forcedly modulated in the entire MDA-MB-231 population, the number of CD133+/EpCAM+ cells significantly decreased, allowing to conclude that, in TNBC derived cells, this PLC isozyme may regulate the size of a cellular subset with high malignant potential, in terms of proliferation, invasion capability and surface expression of tumor stem cell markers.

To better investigate the role of PLC-β2 in modulating the stem cell phenotype of TNBC cells, we also evaluated the surface expression of CD44, a well-described cancer stem cell marker in breast tumors and a negative prognosticator in TNBC [33]. The contemporary staining of MDA-MB-231 with anti-CD44, anti-CD133 and anti-EpCAM antibodies demonstrated that the over-expression of PLC-β2 reduces the number of CD44+/CD133+/EpCAM+ cells. This phenotype, if shared by cells purified from pancreatic cancer (PC), correlates with increased cell growth, migration, clonogenicity, and self-renewal ability [34]. We also found that PLC-β2 induced the appearance of CD44/EpCAM+ cells, usually found in normal breast cells [35], allowing to deduce that, at least in basal-B TNBC derived cells, high levels of this PLC isozyme may revert the malignant phenotype of a small number of cells, thus inducing a “normal-like” phenotype. This is also in agreement with our previous results obtained in low invasive breast tumor derived cells, in which high levels of PLC-β2 characterize cells with an epithelial-like phenotype and counteract the epithelial to mesenchymal shift induced by low oxygen availability [18]. Up-regulation of PLC-β2 in TNBC may then constitute a strategy to reduce the number of cells with high malignant potential that may take advantage of drugs already known to modulate this PLC isozyme [36].

Conclusions

Overall, this work adds substantial information about the role of PLC-β2 in invasive breast tumors, demonstrating that its up-regulation in cells with a basal-B triple-negative phenotype is sufficient to down-modulate the expression of surface antigens crucial for malignancy and to reduce the number of cells with a stem-like phenotype. Given that, unlike other breast cancer subtypes, effective targeted therapy is not currently available for TNBC tumors and considering that the selective removal of BCSCs cells may have a great clinical importance, our results indicate that up-modulation of PLC-β2 is a promising tool for novel therapies aimed to prevent the progression of aggressive breast tumors.

Notes

Abbreviations

APC: 

Allophycocyanin

BCSC: 

Breast cancer stem cell

DAPI: 

4′,6-diamidino-2-phenylindole

DMEM: 

Dulbecco’s Modified Eagle’s Medium

EpCAM: 

Epithelial cell adhesion molecule

FBS: 

Fetal bovine serum

FITC: 

Fluorescein isothiocyanate

MFI: 

Mean fluorescence intensity

PBS: 

Phosphate buffered-saline

PE: 

Phycoerythrin

PLC: 

Phospholipase C

PMT: 

Optimal photomultiplier

RTCA: 

Real-time cell assays

TNBC: 

Triple-negative breast cancer

Declarations

Acknowledgements

Not applicable.

Funding

This work was supported by grants from Italian MIUR (FIRB RBAP10Z7FS_002) to SC and from University of Ferrara (Italy) to VB.

None of the funding sources had any role in the study design, analyses, interpretation of data, or writing of the manuscript, but provided financial means to perform the described experiments and to use the Flow Cytometry Facility of the LTTA Center - University of Ferrara, Italy.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].

Authors’ contributions

FB performed the immunomagnetic cell separation, flow cytometry experiments and drafted the manuscript. SG performed Real Time cells analysis, statistical analyses and drafted the manuscript. PL and MM performed multi-color flow cytometry experiments and revised the manuscript. YA and FV carried out cell culture and protein modulation. SC critically revised the manuscript. VB designed and coordinated the study, planned the experiments and wrote the manuscript. All authors read and approved the final manuscript.

Authors’ information

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara
(2)
Department of Medicine and Aging Science, “G. d’Annunzio” University of Chieti-Pescara
(3)
Center of Aging Sciences and Translational Medicine (CeSI-MeT), “G. d’Annunzio” University of Chieti-Pescara
(4)
College of Medicine, Department of Anatomy, University of Baghdad
(5)
LTTA Centre, University of Ferrara

References

  1. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol. 2014;141:462–77.View ArticlePubMedGoogle Scholar
  2. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–98.View ArticlePubMedGoogle Scholar
  3. Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M, Botti G. Prognostic value of cancer stem cells markers in triple-negative breast cancer. Biomed Res Int. 2015;2015:158682.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–13.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Kagara N, Huynh KT, Kuo C, Okano H, Sim MS, Elashoff D, Chong K, Giuliano AE, Hoon DS. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol. 2012;181:257–67.View ArticlePubMedGoogle Scholar
  6. Geng SQ, Alexandrou AT, Li JJ. Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett. 2014;349:1–7.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J (Engl). 2009;122:2763–9.Google Scholar
  8. Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K, Hirakawa K. CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 2012;7:e45865.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, Yao Z, Dong XY, Zhao N, Liu N. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene. 2013;32:544–53.View ArticlePubMedGoogle Scholar
  10. Nadal R, Ortega FG, Salido M, Lorente JA, Rodriguez-Rivera M, Delgado-Rodriguez M, Macia M, Fernandez A, Corominas JM, Garcia-Puche JL, Sanchez-Rovira P, Sole F, Serrano MJ. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer. 2013;133:2398–407.View ArticlePubMedGoogle Scholar
  11. Ohashi R, Kawahara K, Fujii T, Takei H, Naito Z. Higher expression of EpCAM is associated with poor clinical and pathological responses in breast cancer patients undergoing neoadjuvant chemotherapy. Pathol Int. 2016;66:210–7.View ArticlePubMedGoogle Scholar
  12. Hiraga T, Ito S, Nakamura H. EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation. Int J Cancer. 2016;138:1698–708.View ArticlePubMedGoogle Scholar
  13. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011;102:1107–11.View ArticlePubMedGoogle Scholar
  14. Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Lett. 2016;372:201–9.View ArticlePubMedGoogle Scholar
  15. Waldron NN, Barsky SH, Dougherty PR, Vallera DA. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol. 2014;9:239–49.View ArticlePubMedGoogle Scholar
  16. Polito L, Djemil A, Bortolotti M. Plant toxin-based immunotoxins for cancer therapy: a short overview. Biomedicine; 2016.Google Scholar
  17. Brugnoli F, Grassilli S, Piazzi M, Palomba M, Nika E, Bavelloni A, Capitani S, Bertagnolo V. In triple negative breast tumor cells, PLC-beta2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness. Mol Cancer. 2013;12:165.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. PLC-beta2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential. Mol Carcinog. 2016;12:2210–21.Google Scholar
  19. Bertagnolo V, Benedusi M, Querzoli P, Pedriali M, Magri E, Brugnoli F, Capitani S. PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. Int J Oncol. 2006;28:863–72.PubMedGoogle Scholar
  20. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009;4:e6146.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Cianci E, Recchiuti A, Trubiani O, Diomede F, Marchisio M, Miscia S, Colas RA, Dalli J, Serhan CN, Romano M. Human periodontal stem cells release specialized Proresolving mediators and carry immunomodulatory and Prohealing properties regulated by Lipoxins. Stem Cells Transl Med. 2016;5:20–32.View ArticlePubMedGoogle Scholar
  22. Miscia S, Ciccocioppo F, Lanuti P, Velluto L, Bascelli A, Pierdomenico L, Genovesi D, Di Siena A, Santavenere E, Gambi F, Ausili-Cefaro G, Grimley PM, Marchisio M, Gambi D. A beta (1-42) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease. Neurobiol Aging. 2009;30:394–406.View ArticlePubMedGoogle Scholar
  23. Pierzchalski A, Mittag A, Bocsi J, Tarnok A. An innovative cascade system for simultaneous separation of multiple cell types. PLoS One. 2013;8:e74745.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Bertagnolo V, Benedusi M, Brugnoli F, Lanuti P, Marchisio M, Querzoli P, Capitani S. Phospholipase C-beta 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis. 2007;28:1638–45.View ArticlePubMedGoogle Scholar
  25. Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer. 2013;108:1480–7.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao W, Shao RG. CD1s33(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci. 2012;8:992–1004.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, Krobitsch S, Martowicz A, Gastl G, Spizzo G. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer. 2011;11:45.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Yang F, Cao L, Sun Z, Jin J, Fang H, Zhang W, Guan X. Evaluation of breast cancer stem cells and Intratumor Stemness heterogeneity in triple-negative breast cancer as prognostic factors. Int J Biol Sci. 2016;12:1568–77.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Cantile M, Collina F, D'Aiuto M, Rinaldo M, Pirozzi G, Borsellino C, Franco R, Botti G, Di Bonito M. Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: a case report. Tumori. 2013;99:e245–50.PubMedGoogle Scholar
  30. Gao J, Liu X, Yang F, Liu T, Yan Q, Yang X. By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Oncotarget. 2015;6:27187–98.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Gilboa-Geffen A, Hamar P, Le MT, Wheeler LA, Trifonova R, Petrocca F, Wittrup A, Lieberman J. Gene knockdown by EpCAM aptamer-siRNA chimeras suppresses epithelial breast cancers and their tumor-initiating cells. Mol Cancer Ther. 2015;14:2279–91.View ArticlePubMedGoogle Scholar
  32. Skirecki T, Hoser G, Kawiak J, Dziedzic D, Domagala-Kulawik J. Flow cytometric analysis of CD133- and EpCAM-positive cells in the peripheral blood of patients with lung cancer. Arch Immunol Ther Exp. 2014;62:67–75.View ArticleGoogle Scholar
  33. Xu H, Tian Y, Yuan X, Liu Y, Wu H, Liu Q, Wu GS, Wu K. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. Onco Targets Ther. 2016;9:431–4.PubMedPubMed CentralGoogle Scholar
  34. Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem. 2014;289:14520–33.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B. Enriched CD44(+)/CD24(−) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353:153–9.View ArticlePubMedGoogle Scholar
  36. Bertagnolo V, Marchisio M, Pierpaoli S, Colamussi ML, Brugnoli F, Visani G, Zauli G, Capitani S. Selective up-regulation of phospholipase C-beta2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. J Leukoc Biol. 2002;71:957–65.PubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement